Swipe om te navigeren naar een ander artikel
Prior studies assessing quality of life (QOL) in patients with hepatocellular carcinoma (HCC) primarily included patients with preserved liver function and/or early HCC, leading to overestimation of QOL. Our study’s aim was to evaluate the association of QOL with survival among a cohort of cirrhotic patients with HCC that was diverse with respect to liver function and tumor stage.
We conducted a prospective cohort study among cirrhotic patients with HCC from a large urban safety-net hospital between April 2011 and September 2013. Patients completed two self-administered surveys, the EORTC QLQ-C30 and QLQ-HCC18, prior to the treatment. We used generalized linear models to identify correlates of QOL. Survival curves were generated using Kaplan–Meier analysis and compared using log rank test to determine whether QOL is associated with survival.
A total of 130 treatment-naïve patients completed both surveys. Patients reported high cognitive and social function (median scores 67) but poor global QOL (median score 50) and poor role function (median score 50). QOL was associated with cirrhosis-related (p = 0.02) and tumor-related (p = 0.02) components of Barcelona Clinic Liver Cancer (BCLC) tumor stage. QOL was associated with survival on univariate analysis (HR 0.37, 95 % CI 0.16–0.85) but became nonsignificant (HR 0.82, 95 % CI 0.37–1.80) after adjusting for BCLC stage and treatment. Role functioning was significantly associated with survival (HR 0.40, 95 % CI 0.20–0.81), after adjusting for Caucasian race (HR 0.31, 95 % CI 0.16–0.59), BCLC stage (HR 1.51, 95 % CI 0.21–1.89), and treatment (HR 0.57, 95 % CI 0.33–0.97).
Role function has prognostic significance and is important to assess in patients with HCC.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
El-Serag, H. B. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142(1264–1273), e1261.
Bruix, J., & Sherman, M. (2010). Management of hepatocellular carcinoma: An update. Hepatology, 53, 1–35. CrossRef
Tan, D., Yopp, A., Beg, M. S., Gopal, P., & Singal, A. G. (2013). Meta-analysis: Underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Alimentary Pharmacology & Therapeutics, 38, 703–712. CrossRef
Singal, A. G., Waljee, A. K., Patel, N., Chen, E. Y., Tiro, J. A., et al. (2013). Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. Journal of the National Comprehensive Cancer Network, 11, 1101–1108. PubMed
Singal, A. G., Conjeevaram, H. S., Volk, M. L., Fu, S., Fontana, R. J., et al. (2012). Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prevention, 21, 793–799. CrossRef
Singal AG, X. L, Tiro J, Kandunoori P, Adams-Huet B, et al. (2014) Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. The American Journal of Medicine. doi: 10.1016/j.amjmed.2014.07.027
Fan, S. Y., Eiser, C., & Ho, M. C. (2010). Health-related quality of life in patients with hepatocellular carcinoma: A systematic review. Clinical Gastroenterol and Hepatology, 8(7), 559–564. CrossRef
Mikoshiba, N., Miyashita, M., Sakai, T., Tateishi, R., & Koike, K. (2013). Depressive symptoms after treatment in hepatocellular carcinoma survivors: Prevalence, determinants, and impact on health-related quality of life. Psycho-Oncology, 22(10), 2347–2353. PubMed
Chie, W. C., Blazeby, J. M., Hsiao, C. F., Chiu, H. C., Poon, R. T., et al. (2012). International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. Hepatology, 55, 1122–1129. PubMedCrossRef
de Borja, M. T., Chow, E., Bovett, G., Davis, L., & Gillies, C. (2004). The correlation among patients and health care professionals in assessing functional status using the karnofsky and eastern cooperative oncology group performance status scales. Support Cancer Therapy, 2, 59–63. CrossRef
de Kock, I., Mirhosseini, M., Lau, F., Thai, V., Downing, M., et al. (2013). Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools. Journal of Palliative Care, 29, 163–169. PubMed
- Role functioning is associated with survival in patients with hepatocellular carcinoma
Amit G. Singal
- Springer International Publishing